NO981633L - Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate - Google Patents
Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflateInfo
- Publication number
- NO981633L NO981633L NO981633A NO981633A NO981633L NO 981633 L NO981633 L NO 981633L NO 981633 A NO981633 A NO 981633A NO 981633 A NO981633 A NO 981633A NO 981633 L NO981633 L NO 981633L
- Authority
- NO
- Norway
- Prior art keywords
- analogs
- composition
- active substance
- prodrugs
- solubility
- Prior art date
Links
- 210000004877 mucosa Anatomy 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 7
- 239000013543 active substance Substances 0.000 abstract 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- 239000012071 phase Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 230000003602 anti-herpes Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 abstract 2
- -1 fatty acid ester Chemical class 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 125000003835 nucleoside group Chemical class 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 abstract 1
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 abstract 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 abstract 1
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 abstract 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 abstract 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 abstract 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 abstract 1
- 229960004150 aciclovir Drugs 0.000 abstract 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000000227 bioadhesive Substances 0.000 abstract 1
- 229960001169 brivudine Drugs 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 229960002656 didanosine Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229960004396 famciclovir Drugs 0.000 abstract 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- DLKYYJFLRUUGHJ-SSJCJZGYSA-A fomivirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([S-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DLKYYJFLRUUGHJ-SSJCJZGYSA-A 0.000 abstract 1
- 229960002963 ganciclovir Drugs 0.000 abstract 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 abstract 1
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 abstract 1
- 239000007791 liquid phase Substances 0.000 abstract 1
- 229950005339 lobucavir Drugs 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 229960001179 penciclovir Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229950009279 sorivudine Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940093257 valacyclovir Drugs 0.000 abstract 1
- 229960000523 zalcitabine Drugs 0.000 abstract 1
- 229960002555 zidovudine Drugs 0.000 abstract 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Farmasøytiske sammensetninger for administrering av en aktiv substans til eller gjennom en skadet eller uskadet hud eller mukosaoverflate eller til det orale hulrommet inkludert tennene til et dyr slikt som et menneske. Blandingen har fordelaktige egenskaper med hensyn på frigjøring av den aktive substansen fra blandingen og, videre, er blandingen bioadhesiv. Blandingen innbefatter den aktive substansen og en effektiv mengde av en fettsyreester som, sammen med en flytende fase, kan generere en flytende krystallinsk fase der bestanddelene av blandingen er innesluttet, der den aktive substansen har en løselighet i den flytende krystallinske fasen på det meste 20 mg/g ved 20 °C, og en løselighet i vann på det meste 10 mg/ml ved 20 °C, vannet, der det er passende, er bufret til en pH som er vesentlig lik den pH som er rådende i den flytende krystallinske fasen (pH ca. 3,6-9). Blandingen er spesielt egnet for administrering av substanser som har en veldig lav vannløselighet og som skal bli gitt i en effektiv mengde til en lokalisert region over en tidsperiode. Aktive substanser med spesiell viktighet er anti-herpesvirusagenser inkludert antivirale legemidler og prodroger derav, slik som nukleosider, nukleosid- analoger, fosforylerte nukleosider (nukleotider), nukleotidanaloger og salter, komplekser og prodroger derav; f.eks. guanosinanaloger, deoksyguanosinanaloger, guanin, guaninanaloger, tymidinanaloger, uracilanaloger og adeninanaloger. Spesielt interessante anti-herpesvirusagenser til bruk enten alene eller i kombinasjon i en blanding i henhold til den foreliggende oppfinnelsen er valgt fra acyklovir, famciklovir, deciklovir, penciklovir, zidovudin, ganciklovir, didanosin, zalcitabin, valaciklovir, sorivudin, lobukavir, brivudin, cidofovir, n-dokosanol, ISIS-2922, og prodroger og analoger derav.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK115095 | 1995-10-12 | ||
| PCT/DK1996/000437 WO1997013528A1 (en) | 1995-10-12 | 1996-10-11 | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO981633D0 NO981633D0 (no) | 1998-04-08 |
| NO981633L true NO981633L (no) | 1998-06-04 |
Family
ID=8101575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO981633A NO981633L (no) | 1995-10-12 | 1998-04-08 | Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0871489A1 (no) |
| JP (1) | JPH11513393A (no) |
| AU (1) | AU702030B2 (no) |
| CA (1) | CA2231273A1 (no) |
| FI (1) | FI980822A0 (no) |
| NO (1) | NO981633L (no) |
| WO (1) | WO1997013528A1 (no) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440980B1 (en) | 1996-09-17 | 2002-08-27 | Avanir Pharmaceuticals | Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| CA2286052A1 (en) * | 1997-04-17 | 1998-10-29 | Lise Sylvest Nielsen | A novel bioadhesive drug delivery system based on liquid crystals |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| WO1999007341A1 (en) * | 1997-08-09 | 1999-02-18 | Smithkline Beecham Plc | Compositions for nasal administration |
| ES2202901T3 (es) * | 1997-09-09 | 2004-04-01 | Lyotropic Therapeutics, Inc. | Particulas recubiertas, procedimiento para su fabricacion y uso. |
| SE9703458D0 (sv) * | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
| WO1999060012A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
| US7030155B2 (en) | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| GB9827034D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Manchester | Delivery formulation |
| ATE280571T1 (de) * | 1999-08-06 | 2004-11-15 | Max Delbrueck Centrum | Implantierbares wirkstoffdepot |
| WO2001045727A2 (en) * | 1999-12-20 | 2001-06-28 | New Pharma Research Sweden Ab | Stabilized veterinary compositions comprising more than one antiviral agent |
| DE10057769A1 (de) | 2000-11-22 | 2002-05-23 | Beiersdorf Ag | Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen |
| HUP0400732A3 (en) * | 2001-04-30 | 2007-05-29 | Trommsdorff Arzneimittel | Pharmaceutically active uridine esters |
| US7439271B2 (en) * | 2001-06-27 | 2008-10-21 | The Gillette Company | Reduction of hair growth |
| US20030124196A1 (en) | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| JP2007504256A (ja) * | 2003-09-01 | 2007-03-01 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | 生物活性剤の送達のための組成物及び方法 |
| NZ551990A (en) | 2004-06-04 | 2011-01-28 | Camurus Ab | Liquid depot formulations |
| EP1812022B1 (en) | 2004-09-28 | 2014-01-15 | Atrium Medical Corporation | Stand-alone film and methods for making the same |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036982A2 (en) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
| DE602005026998D1 (de) | 2005-01-14 | 2011-04-28 | Camurus Ab | Somatostatin-analog-formulierungen |
| PL1848403T3 (pl) * | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| SI1845942T1 (sl) * | 2005-01-14 | 2014-06-30 | Camurus Ab | Gnrh analogne formulacije |
| US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
| AU2005325510B2 (en) | 2005-01-21 | 2009-07-02 | Camurus Ab | Pharmaceutical lipid compositions |
| CA2607626A1 (en) * | 2005-05-10 | 2006-11-16 | Novartis Ag | Modified release famciclovir pharmaceutical compositions |
| CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| AU2006304590A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| MX2009004038A (es) | 2006-10-17 | 2009-08-24 | Nuvo Res | Gel de diclofenaco. |
| EP2626091B1 (en) | 2006-11-06 | 2016-09-28 | Atrium Medical Corporation | Coated surgical mesh |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| US8783089B2 (en) * | 2008-06-09 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Device and method for determining the properties of aerosol formulations |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US8618164B2 (en) | 2009-03-31 | 2013-12-31 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
| US8546450B1 (en) | 2009-03-31 | 2013-10-01 | Nuvo Research Inc. | Treatment of pain with topical diclofenac compounds |
| WO2010150262A2 (en) * | 2009-06-25 | 2010-12-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Reverse hexagonal mesophases (hii) and uses thereof |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
| WO2013174978A1 (en) | 2012-05-25 | 2013-11-28 | Camurus Ab | Somatostatin receptor agonist formulations |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| NZ704012A (en) | 2012-07-26 | 2017-09-29 | Camurus Ab | Opioid formulations |
| EP3326613A1 (en) | 2012-07-26 | 2018-05-30 | Camurus AB | Opioid formulations |
| EP3612166A4 (en) | 2017-04-20 | 2020-11-04 | Zeenar Enterprises Pty Ltd | LIQUID CRYSTAL GALENIC FORM FOR THE ADMINISTRATION OF STATIN |
| JP7603972B2 (ja) * | 2018-09-07 | 2024-12-23 | 株式会社ファルネックス | 非ラメラ液晶形成脂質を含む外用剤 |
| CA3117606A1 (en) * | 2018-10-25 | 2020-04-30 | Zeenar Enterprises Pty Ltd | Composition that forms liquid crystalline particles |
| CN111821254B (zh) * | 2019-04-18 | 2021-10-15 | 华东师范大学 | 一种抗病毒水凝胶及其制备方法和应用 |
| CN111759858B (zh) * | 2020-06-02 | 2022-09-20 | 杭州英健生物科技有限公司 | pH敏感型消化道粘膜保护胶及其应用 |
| CN112791047A (zh) * | 2021-01-15 | 2021-05-14 | 中国人民解放军总医院第三医学中心 | 一种白藜芦醇层状液晶及其制备方法 |
| EP4419884A2 (en) * | 2021-10-19 | 2024-08-28 | Sensach AB | Lipid patch |
| WO2023189273A1 (ja) * | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | 生体用組成物 |
| WO2023189270A1 (ja) * | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | 生体用組成物 |
| WO2024068672A1 (en) * | 2022-09-26 | 2024-04-04 | Universität Bern | Structured lipid compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2631282A1 (de) * | 1976-07-12 | 1978-01-19 | Kali Chemie Pharma Gmbh | Verfahren zur erhoehung der loeslichkeit und des dispersitaetsgrades von schwerloeslichen arzneistoffen zum zwecke deren applikation in gelatinekapseln |
| SE457933B (sv) * | 1987-07-06 | 1989-02-13 | Larsson Kare | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion |
| DK0448091T3 (da) * | 1990-03-23 | 1999-05-03 | Yoshitomi Pharmaceutical | Farmaceutisk præparat indeholdende et i ringe grad vandopløseligt medikament |
| CA2186750C (en) * | 1994-03-30 | 2008-08-05 | Jens Hansen | Use of fatty acid esters as bioadhesive substances |
-
1996
- 1996-10-11 AU AU72792/96A patent/AU702030B2/en not_active Ceased
- 1996-10-11 JP JP9514651A patent/JPH11513393A/ja active Pending
- 1996-10-11 CA CA002231273A patent/CA2231273A1/en not_active Abandoned
- 1996-10-11 EP EP96934441A patent/EP0871489A1/en not_active Withdrawn
- 1996-10-11 WO PCT/DK1996/000437 patent/WO1997013528A1/en not_active Application Discontinuation
-
1998
- 1998-04-08 NO NO981633A patent/NO981633L/no not_active Application Discontinuation
- 1998-04-09 FI FI980822A patent/FI980822A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997013528A1 (en) | 1997-04-17 |
| AU702030B2 (en) | 1999-02-11 |
| FI980822A (fi) | 1998-04-09 |
| AU7279296A (en) | 1997-04-30 |
| JPH11513393A (ja) | 1999-11-16 |
| NO981633D0 (no) | 1998-04-08 |
| FI980822A0 (fi) | 1998-04-09 |
| CA2231273A1 (en) | 1997-04-17 |
| EP0871489A1 (en) | 1998-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO981633L (no) | Farmas÷ytisk blanding for administrering av en aktiv forbindelse til eller gjennom hud eller en mukosaoverflate | |
| Mahmoud et al. | Antiviral nucleoside and nucleotide analogs: a review | |
| KR900015742A (ko) | 항 비루스 제 | |
| MY121839A (en) | Antiviral purine derivatives | |
| EA005774B1 (ru) | 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ | |
| CZ20023051A3 (cs) | Nukleosidový analog a jeho použití | |
| RU2006147216A (ru) | Бета-l-2` дезокси-нуклеозиды для лечения гепатита в | |
| BR0008498A (pt) | Método de promoção de hidratação de mucosas com certos difosfatos de uridina, adenina e citidina e seus análogos | |
| WO2006113204A2 (en) | Thymidine derivatives for treatmemt of kaposi's sarcoma | |
| Balzarini | Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors | |
| HU198394B (en) | Process for production of synergetic antiviral medical composition | |
| Herdewijn | Novel nucleoside strategies for anti-HIV and anti-HSV therapy | |
| SI9820003A (sl) | Zdravljenje bolezni povezano s citokini | |
| KR20010082282A (ko) | Β 형 간염 바이러스를 치료하기 위한 복합 요법 | |
| WO2014160369A1 (en) | Combined systemic and topical treatment of disordered tissues | |
| Gangadhara et al. | Hydroxy fatty acids for the delivery of dideoxynucleosides as anti-HIV agents | |
| US20240199662A1 (en) | Prodrugs of l-bhdu and methods of treating viral infections | |
| EP1778254A2 (en) | Prodrugs activated by rna-dependent dna-polymerases | |
| US4044122A (en) | Method of treating herpes virus hominis infections | |
| US20100137341A1 (en) | Dna polymerase inhibitors composition and methods | |
| RU98100411A (ru) | Производные ацикловира для локального применения | |
| Egron et al. | Investigations of nucleoside H-phosphonamidate in the design of nucleotide prodrug | |
| US20090004101A1 (en) | Method and Means for Enhanced Pulmonary Drug Delivery | |
| ECSP993155A (es) | Compuestos quimicos | |
| WO1993000099A2 (de) | Verwendung von pyrimidin- und purinnucleosiden zur prophylaxe und/oder behandlung von durch adenoviren verursachten infektionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |